Feasibility and safety of autologous cord blood derived cell administration in extremely preterm infants: a single-centre, open-label, single-arm, phase I trial (CORD-SaFe study)

Update your browser to view ScienceDirect correctly.

Your technical details and browser version:

Request ID: 8f5b24b77f4f7aeb-LAX IP: 47.97.18.252 UTC time: 2024-12-21T22:00:10+00:00 Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4